NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

NICE Technology Appraisal guidance no.'s 140; Infliximab for subacute manifestations of ulcerative colitis and 163; Infliximab for the treatment of acute exacerbations of ulcerative colitis

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
 Manufacturers/sponsors Merck Sharp and Dohme (infliximab) <u>Patient/carer groups</u> Afiya Trust Black Health Agency Bladder and Bowel Foundation Chinese National Healthy Living 	 General Board of Community Health Councils in Wales British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services
 Contrese National Healthy Living Centre Colostomy Association Counsel and Care 	 Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency
 Crohn's and Colitis UK Equalities National Council 	 National Association of Primary Care NHS Alliance
 Ia: Ileostomy and Internal Pouch Support Group IBD Club 	 NHS Commercial Medicines Unit NHS Confederation NHS Quality Improvement Scotland
 Muslim Council of Britain Muslim Health Network 	 Public Health Wales NHS Trust Scottish Medicines Consortium
 Ostomy Lifestyle Centre South Asian Health Foundation Specialised Healthcare Alliance Ulcerative Colitis UK 	 <u>Possible comparator manufacturers</u> AAH Pharmaceuticals (sulfasalazine, azathioprine, ciclosporin, mesalazine) Abbott laboratories (adalimumab)
 <u>Professional groups</u> Association of Coloproctology of Great 	Actavis UK (azathioprine, sulfasalazine)Almirall (balsalazide)
 Britain and Ireland Association of Surgeons of Great Britain and Ireland 	 Arrow generics (azathioprine) Almus pharmaceuticals (azothiaprine, sulfasalazine)
 British Association for Services to the Elderly 	 Aspen Europe (azathioprine, mercaptopurine)
 British Geriatrics Society British Society of Gastroenterology Primary Care Society for 	 Dexcel-Pharma (ciclosporin) Dr Falk Pharma UK (mesalazine, mercaptopurine)
Gastroenterology	Ferring Pharmaceuticals (mesalazine)

National Institute for Health and Clinical Excellence

NICE Technology Appraisal guidance no.'s 140; Infliximab for subacute manifestations of ulcerative colitis and 163; Infliximab for the treatment of acute exacerbations of ulcerative colitis Issue date: March 2011

Consultees	Commentators (no right to submit or appeal)
 Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine United Kingdom Clinical Pharmacy Association Others Department of Health NHS Devon NHS Oxfordshire Welsh Assembly Government 	 Focus Pharmaceuticals (azathioprine) Forest Laboratories UK (prednisolone – foam and enema) Genesis pharmaceuticals (sulfasalazine, azathioprine, mesalazine) Meda Pharmaceuticals (hydrocortizone -foam) Metwest pharmaceuticals (hydrocortizone -foam) Metwest pharmaceuticals (sulfasalazine, azathioprine, mesalazine) Mylan (sulfasalazine, azathioprine, ciclosporin) Novartis Pharmaceuticals (ciclosporin) Pfizer (sulfasalazine) Ranbaxy UK (sulfasalazine) Rosemont Pharmaceuticals (sulfasalazine) Sandoz (azathioprine, mesalazine, sulfasalazine) Shire Pharmaceuticals (mesalazine) Teva UK (azathioprine, sulfasalazine) Tilomed (azathioprine, sulfasalazine) UCB Pharmaceuticals (olsalazine) Warner Chilcott UK (mesalazine) Warner Chilcott UK (mesalazine) Warner Chilcott UK (mesalazine) Warner Chilcott UK (mesalazine) Wagmade (sulfasalazine, mesalazine, mercaptopurine) Relevant research groups CORE (Digestive Disorders Foundation) MRC Clinical Trials Unit National Institute for Health Research Policy Research Institute on Ageing and Ethnicity Research Institute for the Care of Older People Assessment Group toc National Institute for Health Research Health Technology Assessment Programme

National Institute for Health and Clinical Excellence

Consultees	Commentators (no right to submit or appeal)
	 <u>Associated Guideline groups</u> National Clinical Guideline Centre
	Associated Public Health groups none

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the

lists in the matrix, and which organisations we should include that have a particular

focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

National Institute for Health and Clinical Excellence

NICE Technology Appraisal guidance no.'s 140; Infliximab for subacute manifestations of ulcerative colitis and 163; Infliximab for the treatment of acute exacerbations of ulcerative colitis Issue date: March 2011

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).